Orlistat is the only FDA approved PL inhibitor for obesity treatment [8]; it is a saturated derivative of lipstatin, a potential natural PL inhibitor, isolated from the actinobacterium Streptomyces toxytricini [9]. This evidence concerns the gene PNLIP and obesity disorder.